-
公开(公告)号：US11110157B2
公开(公告)日：2021-09-07
申请号：US16384904
申请日：2019-04-15
Applicant: CureVac AG
Inventor： Mariola Fotin-Mleczek , Karl-Josef Kallen , Jan C. Schmollinger
IPC: A61K39/00 , A61K39/39 , A61K39/395 , C07K16/28 , C07K16/30
Abstract: The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.
-
公开(公告)号：US10918740B2
公开(公告)日：2021-02-16
申请号：US16039988
申请日：2018-07-19
Applicant: CureVac AG
Inventor： Mariola Fotin-Mleczek , Aleksandra Kowalczyk , Regina Heidenreich , Patrick Baumhof , Jochen Probst , Karl-Josef Kallen
IPC: C07H21/04 , A61K48/00 , A61K38/19 , A61K38/20 , A61K39/395 , C07K16/28 , C07K16/34 , A61K39/12 , A61K31/7105 , A61K31/713 , C12N15/117 , A61K9/00 , A61K38/17 , A61K39/145 , A61K39/39 , A61K45/06 , C07K16/30 , C12N7/00 , A61K39/00
Abstract: The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.
-
公开(公告)号：US10588959B2
公开(公告)日：2020-03-17
申请号：US15048561
申请日：2016-02-19
Applicant: CureVac AG
Inventor： Karl-Josef Kallen , Thomas Kramps , Margit Schnee , Daniel Voss
IPC: A61K39/155 , A61K39/145 , A61K39/12 , C07K14/005 , C12N7/00 , A61K39/00
Abstract: The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.
-
公开(公告)号：US09974845B2
公开(公告)日：2018-05-22
申请号：US14769720
申请日：2014-02-21
Applicant: CureVac AG
Inventor： Mariola Fotin-Mleczek , Karl-Josef Kallen , Jochen Probst
IPC: A61K31/713 , A61K39/00 , A61K39/395 , C07K16/28 , A61K38/00 , A61K39/39
CPC classification number: A61K39/0011 , A61K39/0005 , A61K39/39 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61K2039/53 , A61K2039/55516 , C07K16/2803 , C07K16/2818 , C07K2317/76 , Y02A50/491 , A61K2300/00
Abstract: The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.
-
公开(公告)号：US11266735B2
公开(公告)日：2022-03-08
申请号：US16781781
申请日：2020-02-04
Applicant: CureVac AG
Inventor： Karl-Josef Kallen , Thomas Kramps , Margit Schnee , Daniel Voss
IPC: A61K39/155 , A61K39/145 , A61K39/12 , C07K14/005 , C12N7/00 , A61K39/00
Abstract: The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.
-
公开(公告)号：US12178863B2
公开(公告)日：2024-12-31
申请号：US17396760
申请日：2021-08-08
Applicant: CureVac AG
Inventor： Mariola Fotin-Mleczek , Karl-Josef Kallen , Jan C. Schmollinger
Abstract: The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.
-
公开(公告)号：US11672856B2
公开(公告)日：2023-06-13
申请号：US16910845
申请日：2020-06-24
Applicant: CureVac AG
Inventor： Karl-Josef Kallen , Thomas Kramps , Margit Schnee , Benjamin Petsch , Lothar Stitz
IPC: A61K39/145 , A61K39/155 , A61K39/12 , A61K47/59 , A61K47/64 , A61K47/69 , A61P31/16 , A61K39/00 , A61K45/06
CPC classification number: A61K39/155 , A61K39/00 , A61K39/12 , A61K39/145 , A61K45/06 , A61K47/59 , A61K47/6455 , A61K47/6921 , A61P31/16 , A61K2039/53 , A61K2039/54 , A61K2039/55 , A61K2039/55583 , A61K2039/572 , A61K2039/575 , A61K2039/6031 , A61K2039/622 , C12N2760/16134 , C12N2760/18534 , C12N2760/18571 , Y02A50/30
Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
-
公开(公告)号：US10729761B2
公开(公告)日：2020-08-04
申请号：US16273525
申请日：2019-02-12
Applicant: CureVac AG
Inventor： Karl-Josef Kallen , Thomas Kramps , Margit Schnee , Benjamin Petsch , Lothar Stitz
IPC: A61K39/145 , A61K48/00 , A61K39/155 , A61K39/12 , A61K47/59 , A61K47/64 , A61K47/69 , A61P31/16 , A61K39/00 , A61K45/06
Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
-
公开(公告)号：US10596252B2
公开(公告)日：2020-03-24
申请号：US16179990
申请日：2018-11-04
Applicant: CureVac AG
Inventor： Karl-Josef Kallen , Thomas Kramps , Margit Schnee , Benjamin Petsch , Lothar Stitz
IPC: A61K39/155 , A61K39/12 , A61K39/145 , A61K47/59 , A61K47/64 , A61K47/69 , A61P31/16 , A61K39/00 , A61K45/06
Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.
-
公开(公告)号：US10434158B2
公开(公告)日：2019-10-08
申请号：US15890736
申请日：2018-02-07
Applicant: CureVac AG
Inventor： Mariola Fotin-Mleczek , Karl-Josef Kallen , Jochen Probst
IPC: C07K16/28 , A61K39/395 , A61K39/00 , A61K39/39
Abstract: The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.
